Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review

Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review

BackgroundBullous pemphigoid (BP) is the most common autoimmune subepidermal bullous disease of the skin. First-line treatment of systemic corticosteroids may cause serious adverse events. Rituximab, omalizumab, and dupilumab should be explored as alternative treatment options to improve outcomes.Ob...

Full description

Bibliographic Details
Main Authors: Peng Cao, Wenjing Xu, Litao Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Immunology
Subjects:
rituximab
omalizumab
dupilumab
biologics
bullous pemphigoid
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.928621/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.928621/full

Similar Items